Work Here?
Overview
Company Does Not Provide H1B Sponsorship
IONLACE is a biotech-focused R&D company that builds and funds science projects in biotechnology, molecular biology, and advanced materials. It hires highly skilled, highly curious scientists—“rebel scientists”—and gives them resources and freedom to pursue ambitious, real-world-impact ideas. The company operates in innovation hubs like Stockholm and Copenhagen to accelerate research and development. Revenue comes from advancing R&D projects toward commercialization through patents, partnerships with larger companies, and market-ready products, as well as grants and venture funding. IONLACE differentiates itself by prioritizing rapid execution and bold, high-risk research led by top talent, aiming to stay ahead in a competitive field. Its goal is to shape the future of scientific and technological progress by turning breakthroughs into practical applications through collaborations, licensing, and new products.
About Ionlace
Industries
Venture Capital
Industrial & Manufacturing
Biotechnology
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
Solna kommun, Sweden
Founded
2023
Get referred to Ionlace
See people who can refer or advise you
Simplify's Take
What believers are saying
- LinkedIn updated September 22, 2026, says Ionlace is hiring multiple positions.
- Mats Berggren listed $4M backing from US and EU investors in 2026.
- The company’s Stockholm HQ and Cambridge presence tap dense Nordic and UK biotech talent.
What critics are saying
- Ionlace shows no public product revenue, making fundraising the only obvious runway engine.
- LinkedIn reports 11-50 employees; one failed financing round can halt experiments quickly.
- Competing AI-biotech platforms from Isomorphic Labs and Generate:Biomedicines can outspend Ionlace by 2027.
What makes Ionlace unique
- Lab-in-the-loop AI plus synthetic biology targets programmable biologics, not generic biotech tooling.
- Leadership spans Stockholm, Cambridge, and Karolinska, pairing protein design with wet-lab execution.
- Johan Jessen described a 1/20-cost, 1/8-time biomarker binder platform in 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Paid Vacation
401(k) Retirement Plan
Company News
Ionlace raised pre-seed capital funding involving Ionlace with investors including Acme Capital, Heartcore, 201 Ventures. Nordic9.com tracks European startup funding, M&A and investor activity.
There are no jobs for Ionlace right now.
Find jobs on Simplify and start your career today
About Ionlace
Industries
Venture Capital
Industrial & Manufacturing
Biotechnology
Company Size
1-10
Company Stage
N/A
Total Funding
N/A
Headquarters
Solna kommun, Sweden
Founded
2023
There are no jobs for Ionlace right now.
Find jobs on Simplify and start your career today